Original Primary Outcome: Safety (review of adverse events)

Current Secondary Outcome:

• Investigators Global Assessment of the Clinical Condition [ Time Frame: Visit 3, day 8 ]
  The efficacy endpoints for this study consisted of reduction of inflammation as measured by the IGA of the clinical condition. Changes in clinical condition measured as improved, unchanged or worsened.
• Assessment of Ocular Signs in the Study Eye - Visit 1 [ Time Frame: Visit 1 (day 1) ]
  Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.
• Assessment of Ocular Signs in the Study Eye - Visit 2 [ Time Frame: Visit 2 (day 8) ]
  Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.
• Assessment of Ocular Signs in the Study Eye - Visit 3 [ Time Frame: Visit 3 (day 15) ]
  Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe.

Original Secondary Outcome: Efficacy (number of study eyes with clinical improvement)

Information By: Bausch & Lomb Incorporated

Dates:
Date Received: January 8, 2007
Date Started: November 2006
Date Completion:
Last Updated: September 30, 2011
Last Verified: September 2011